Work

Reduced Intensity Allogeneic Stem Cell Transplantation Followed By Adoptive Cellular Immunotherapy with Donor Derived LMP Specific-CTLs in Patients with EBV Positive Refractory or Recurrent Hodgkin Lymphoma: A Lymphoma Cell Therapy Consortium (LCTC) Trial

Year: 2015

Type: article

Abstract: Lymphoma represents the third most common cancer under 15yrs of age and the most common cancer in adolescents and young adults.(Hochberg/Cairo, BJH 2009) Hodgkin Lymphoma occurs in approximately 7,500 people per yr in the U.S. EBV infection has been suggested to be one of several causative possibilities in its pathogenesis with about 40% of HL being EBV-associated. Autologous T cells directed to LMP1/2 antigens can induce durable responses in high risk patients without significant toxicity.(Bollard, JCO 2014) Although there have been significantly improved outcomes, those with progressive or relapsed disease often require alternative strategies with limited good options.

Source: Transplantation and Cellular Therapy

DOI: 10.1016/j.bbmt.2014.11.299